[
  {
    "ts": null,
    "headline": "Verona Pharma (VRNA) Jumps 125% YTD; Merck $10-Billion Acquisition Bolsters Sentiment",
    "summary": "We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of the top-performing mid-cap companies of the first half of the year. Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading day of 2024, with its […]",
    "url": "https://finnhub.io/api/news?id=f700f1d37cc58e919dcc990b3c76337e159b486ee9747a0028278fb4b5d4c546",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752782082,
      "headline": "Verona Pharma (VRNA) Jumps 125% YTD; Merck $10-Billion Acquisition Bolsters Sentiment",
      "id": 136005606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of the top-performing mid-cap companies of the first half of the year. Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading day of 2024, with its […]",
      "url": "https://finnhub.io/api/news?id=f700f1d37cc58e919dcc990b3c76337e159b486ee9747a0028278fb4b5d4c546"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript",
    "summary": "Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript",
    "url": "https://finnhub.io/api/news?id=516e7409e353ad3a4a3002a3635ab39e25d2c94677f6be8e63a970869e581a6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752776670,
      "headline": "Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript",
      "id": 135998567,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=516e7409e353ad3a4a3002a3635ab39e25d2c94677f6be8e63a970869e581a6d"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f5eb2593fce183c2d0a8065d72fa6d725667e099ede29ee51b233e755846c4a5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752770040,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "id": 136002785,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f5eb2593fce183c2d0a8065d72fa6d725667e099ede29ee51b233e755846c4a5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?",
    "summary": "LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.",
    "url": "https://finnhub.io/api/news?id=f68a23763a8cc6c1054870a6bb24f1e66abc3d1c622ead267d08ccc751476d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759900,
      "headline": "Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?",
      "id": 135993033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.",
      "url": "https://finnhub.io/api/news?id=f68a23763a8cc6c1054870a6bb24f1e66abc3d1c622ead267d08ccc751476d51"
    }
  },
  {
    "ts": null,
    "headline": "Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business",
    "summary": "Merck aims to boost its business by buying Verona Pharma for $10 billion.  Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.  One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda.",
    "url": "https://finnhub.io/api/news?id=f678b37439380fd840bf9992413e1fe274e6345aff09382b42ef1279404ca593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752754500,
      "headline": "Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business",
      "id": 135993385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck aims to boost its business by buying Verona Pharma for $10 billion.  Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.  One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda.",
      "url": "https://finnhub.io/api/news?id=f678b37439380fd840bf9992413e1fe274e6345aff09382b42ef1279404ca593"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector",
    "summary": "Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth potential, and balanced risk profile.",
    "url": "https://finnhub.io/api/news?id=3d3853fa2e7bee6d70f67416c883703b1a0e5c738e0a9923dcf3cb21c8484e08",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752751964,
      "headline": "Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector",
      "id": 135992662,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351084382/image_1351084382.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth potential, and balanced risk profile.",
      "url": "https://finnhub.io/api/news?id=3d3853fa2e7bee6d70f67416c883703b1a0e5c738e0a9923dcf3cb21c8484e08"
    }
  }
]